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Abstract 
Tissue resident lymphocytes are present within many organs, and are presumably 
transferred at transplantation, but their impact upon host immunity is unclear. Here we 
examine whether transferred donor natural regulatory CD4 T cells (nT-regs) inhibit host 
alloimmunity and prolong allograft survival. Transfer of donor-strain lymphocytes was first 
assessed by identifying circulating donor-derived CD4 T cells in 21 consecutive human lung 
transplant recipients, with three patterns of chimerism apparent: transient; intermediate; 
and persistent (detectable for up to 6 weeks, 6 months, and beyond one year, respectively). 
The potential for transfer of donor nT-regs was then confirmed by analysis of leucocyte 
filters recovered from ex-vivo normothermic perfusion circuits of human kidneys retrieved 
for transplantation. Finally, in a murine model of cardiac allograft vasculopathy, depletion of 
donor CD4 nT-regs prior to organ retrieval resulted in markedly accelerated heart allograft 
rejection and augmented host effector antibody responses. Conversely, adoptive transfer or 
purified donor-strain nT-regs inhibited host humoral immunity and prolonged allograft 
survival, and more effectively so than following administration of recipient nT-regs. In 
summary, following transplantation, passenger donor-strain nT-regs can inhibit host 
adaptive immune responses and prolong allograft survival. Isolated donor-derived nT-regs 
may hold potential as a cellular therapy to improve transplant outcomes.   
 
Introduction 
Although still considered a novel technology, ex vivo perfusion of retrieved organs from 
deceased donors is likely to become widely adopted in the near future (1, 2). Ex vivo 
perfusion offers the potential to assess the viability of organs prior to transplantation, and 
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to extend the acceptable period between retrieval and implantation. It may also enable 
targeting of the isolated organs with specific therapies aimed at prolonging allograft survival 
(3). One particular focus of such strategies is likely to be donor-derived T cell populations 
(naïve or memory) that are resident within the graft (4, 5).  
 
We have recently reported that passenger T cells are present within human donor organs 
retrieved for transplantation and, using murine transplant models, have demonstrated that 
donor T effector cells can augment host alloimmune responses directed against the allograft 
(6). Thus, although seemingly counterintuitive, these passenger lymphocytes contribute to 
rejection of the organ. Here, we examine whether donor-derived natural regulatory T cells 
(nT-regs) can, conversely, prolong allograft survival. 
 
Materials and Methods 
 
Identification of circulating donor CD4 T lymphocytes in human lung transplant recipients 
Following adult deceased donor lung or heart plus lung transplantation, blood from 
consenting recipients was sampled at pre-determined time points (initially weekly for first 
two months after transplant, and monthly / bi-monthly thereafter) and donor CD4 T 
lymphocytes identified by flow cytometry, on the basis of expression of MHC alloantigen. 
Briefly, peripheral blood mononuclear cells (PBMCs) were labelled with anti-CD3-FITC 
(fluorescein isothiocyanate, clone HIT3a) and anti CD4 PE (Phycoerythrin, clone RPA-T4) 
monoclonal antibodies (both BD Biosciences, Oxford, UK) and with the relevant MHC class I 
HLA-specific biotinylated antibody, selected to bind exclusively to donor (but not recipient) 
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HLA class I MHC alloantigen (See Table s1; kindly gifted by Prof. Frans Claas, Leiden 
University Medical Center, Leiden, Netherlands). Cells were further labelled with 
allophycocyanin (APC)-conjugated streptavidin (Invitrogen, Paisley UK) and donor cells 
identified using BD FACSCantoTM flow cytometer with BD FACSDiva software (BD 
Pharmingen, Berkshire UK). Pure populations of donor and recipient CD4 T cells (obtained 
from donor spleen / lymph nodes and recipient blood prior to transplantation, respectively) 
were used as positive and negative controls for donor lymphoctyte identification. Positive 
identification of donor CD4 T cells in test samples was based on relative intensity of staining 
of control donor to recipient cells (Figure s1).  
 
The human lung study received favorable ethical opinion by the Cambridgeshire 4 Research 
Ethics Committee and was approval by the Health Research Authority. The study was 
registered with the National Institute of Health Research (NIHR) Clinical Research Network 
Portfolio. 
 
Characterisation of lymphocyte subsets released during ex-vivo normothermic perfusion 
Kidneys underwent one hour of normothermic machine perfusion, as previously described 
(32), with a leukocyte filter, RS1VAE (Haemonetics, Coventry, UK ) in the circuit. After 1 
hour, the filter was removed and flushed in an antegrade direction with 400 mL of sterile 
phosphate-buffered saline (PBS). The filters were then incubated with 20 mL of Trypsin-
ethylenediaminetetraacetic acid (EDTA) at 37°C for 10 minutes, and cells recovered by 
flushing in a retrograde direction with 400 mL of sterile PBS. Cell pellets were cryopreserved 
with 10% DMSO (dimethyl sulfoxide) in fetal calf serum (FCS), and stored at -80°C. For flow 
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cytometry characterization, cells were quickly thawed in Dulbecco′s Modified Eagle′s 
Medium (Gibco, D5030, ThermoFisher Scientific, UK) with 2% FCS and resuspended in FACS 
buffer (PBS, 1% FCS, 0.02% sodium azide). Cells were stained in FACS buffer for 30 min on 
ice with the following antibodies: PE anti-human CD127 (clone eBioRDR5, ThemoFisher 
Scientific), Brilliant Blue 515 anti-human CD25 (clone 2A3, BD Pharmingen), APC Cy7 anti-
human CD3 (clone SK7, BioLegend, London UK), PE Cy7 anti-human CD4 (clone SK3, BD 
Pharmingen), and dead cell exclusion dye 7-aminoactinomycin D (BD Pharmingen). Cells 
were washed twice with FACS buffer after antibody staining, and cell events were collected 
on FACSCanto II analyzers (BD Pharmingen) and analyzed with FlowJo software (Oregan, 
USA). The human kidney study had received favourable ethical approval Newcastle & North 
Tyneside 2 Research Ethics Committee REC (15/NE/0408).  
 
Animals 
C57BL/6J (H-2
b
; B6) were purchased from Charles River Laboratories (Margate, UK). Bm12 
mice (B6(C)-H2-Ab1bm12/KhEgJ [H-2bm12]), and H-2
b
 T cell receptor-deficient mice (Tcrbd
-/-
 
(B6.129P2-Tcrb
tm1Mom
Tcrd
tm1Mom
/J) (33)) were purchased from the Jackson Laboratory (Bar 
Harbor, ME, USA). 
 
 
Heterotopic heart transplantation 
Vascularized cardiac allografts were transplanted intra-abdominally as previously described 
(34, 35). Heart graft survival was monitored by daily abdominal palpation with rejection 
defined as cessation of a detectable beat. Grafts were excised at predetermined time points 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
after transplantation and stored at -80°C or fixed in 10% buffered formalin. In certain 
experiments, recipient B6 mice were depleted of CD4 T-regs by treatment with 0.5mg of 
anti-CD25 mAb (PC-61, Bio X Cell, West Lebanon, NH, USA) i.p. on day -1 followed by 0.25 
mg i.p. on days 1,3,5,and 7, in relation to bm12 heart graft transplantation. Donor T-reg 
depletion was achieved by administering 0.5mg of anti-CD25 mAb (PC-61) i.p. on days -6 
and -2 prior to heart allograft retrieval. Pilot experiments confirmed that this treatment 
resulted in depletion of typically 85-90% of FoxP3
+ve 
splenic CD4 T cells.   
 
Adoptive transfer of donor/recipient-derived nT-regs 
Recipient B6 mice were adoptively transferred by tail-vein intravenous injection with 1 x 10
6
 
nT-regs derived from B6 or bm12 animals on the first post-operative day after bm12 cardiac 
transplantation. nT-regs were purified from spleens of naïve B6 or bm12 animals using the 
CD4
+
CD25
+
 Regulatory T Cell Isolation Kit (Miltenyi Biotec, Auburn CA, USA) and an 
autoMACS separator (Miltenyi); cell purity (typically >90% CD25
+ve 
CD4
+ve
) was analysed by 
flow cytometry prior to injection. 
 
Quantification of humoral autoantibody responses 
Antinuclear autoantibody responses were determined by HEp-2 indirect 
immunofluorescence (The Binding Site, Birmingham, UK) as described previously (36), by 
incubating test sera on slides coated with HEp-2 cells and detecting bound antibody with 
FITC-conjugated goat anti-mouse IgG (STAR 70; Serotec, Oxford, UK). For each test serum, 
photomicrographs were taken, and the intensity of staining was determined by integrated 
morphometric analysis using MetaMorph software. The fluorescence value was then 
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derived by comparison with a standard curve, obtained for each assay by serial dilutions of a 
pooled hyperimmune serum that was assigned an arbitrary value of 1000 fluorescence 
units. 
 
Histopathology 
Cardiac allograft vasculopathy was assessed on elastin van Gieson-stained paraffin sections 
by morphometric analysis as previously described (36). Luminal stenosis [percentage cross-
sectional area luminal stenosis = (area within internal elastic lamina - area of lumen)/area 
within internal elastic lamina x 100]. All elastin-positive vessels in each section were 
evaluated, with approximately 10 vessels/heart analysed.  
 
Statistics 
Data were presented as mean ± S.D. where appropriate. Mann Whitney tests were used for analysis of non-
parametric data. Two-way ANOVA was employed for comparison of antinuclear and anti-vimentin 
autoantibody responses. Graft survival was depicted using Kaplan-Meier analysis and groups compared by log-
rank (Mantel-Cox) testing. Analysis was conducted using GraphPad 4 (Graph- Pad Software, San Diego, CA, 
USA). Values of P < 0.05 were considered significant. 
 
Results  
 
Different CD4 T cell lineages are released from human allografts  
Having previously demonstrated the presence of CD4 T effector cells within human organs 
retrieved for transplantation (6, 7), we sought to determine whether donor CD4 T cells, and 
specifically, donor T-regs, could potentially also be released into the recipient’s circulation 
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following transplantation. Human lung transplant recipients (n=21) were therefore followed 
for the first year following transplantation, and the presence of circulating donor-derived 
CD4 T cells determined by surface expression of mismatched HLA donor antigen (Figure s1). 
As shown in Figure 1, donor-derived CD4 T cells were detectable immediately following 
transplantation in all patients, representing 0.06% and 6% of the total CD4 T cell population 
detectable in the recipient (mean chimerism at 1 week; 1.54 ± 1.41%). Numbers of cells 
recovered were too small to definitely assess different T cell lineages, but RT-PCR gene 
expression analysis of flow sorted donor CD4 T cells (not shown) revealed profiles consistent 
with naïve and CD44
hi
 memory CD4 T cells, albeit samples from the same patient varied 
markedly at different time points, with no consistent phenotype observed. Notwithstanding, 
three different patterns of chimerism were evident (Figure 1a): transient (detectable for up 
to 6 weeks); intermediate (detectable for up to 6 months) or persistent (lasting for over a 
year).  
 
The release of donor T-regs was then assessed by analysis of leucocyte filters recovered 
from human kidneys that had been obtained using standard retrieval techniques, but then 
perfused normothermically ex vivo using leucocyte depleted blood (2). Hence leucocytes 
captured by the filter in the circuit reflect those cells that would be released into the 
recipient circulation had the organ been transplanted without first been subject to ex vivo 
perfusion. CD4 T cells were readily recovered from the filters, and represented 6.57 ± 1.30% 
of the total lymphocyte population (Figure 1b). A small, but consistently present, population 
of CD4 T cells with surface T-reg phenotype (CD25
pos
CD127
lo
; 6.74 ± 4.73% of CD4 T cells) 
was also recovered (Figure 1b). T cells were not evident upon analysis of the stored 
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leucocyte-depleted blood used in the circuit (not shown), suggesting that the T-reg 
population had been released upon re-perfusion of the retrieved kidneys.  
 
T-reg depletion results in augmented humoral immunity and accelerated allograft rejection 
The influence of donor and recipient T-regs on allograft outcomes was then examined using 
an MHC class II-mismatched murine model of chronic heart allograft rejection. Our previous 
work has highlighted that chronic allograft vasculopathy (CAV) in this model is associated 
with development of effector autoantibody responses that are triggered by graft-versus-
host recognition of MHC class II on host B cells by passenger donor CD4 T lymphocytes (6-8). 
In comparison to unmodified wild-type (WT) C57BL/6 recipients, depletion of the T-reg 
population by administration of anti-CD25 mAb to C57BL/6 mice at, and following, 
transplantation with bm12 (B6(C)-H2-Ab1bm12/KhEgJ) heart allografts resulted in much 
more rapid heart graft rejection, and was associated with markedly augmented host 
autoantibody responses (Figures 2A and 2B). This accelerated rejection was nevertheless 
dependent upon adoptive transfer of donor CD4 T cells, because heart allografts from T cell 
deficient bm12.TCR
-/-
 donors did not trigger host autoantibody responses and survived 
indefinitely, without developing CAV (Figure 2C), even following recipient T-reg depletion 
(Figure 2A). This suggests that the T-regs were principally influencing the donor T cell / host 
B cell axis.  
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Donor-derived T-regs prolong allograft survival more effectively than recipient T-regs 
In the above experiments, anti-CD25 treatment of the recipient was continued after 
transplantation; raising the possibility that transferred donor T-regs were also targeted. 
Notably, transplantation of heart allografts from donor bm12 mice that had received anti-
CD25 treatment prior to organ retrieval also triggered markedly augmented autoantibody 
responses in WT C57BL/6 recipient mice, and heart allografts were rejected at least as 
rapidly as following recipient T-reg depletion (Figures 3A and 3B). To test the comparative 
efficacy of donor versus recipient derived T-regs in preventing allograft rejection, WT 
C57BL/6 recipients of unmodified bm12 heart grafts were additionally transferred with nT-
regs (9, 10), purified from either the recipient or donor strains. Interestingly, whereas 
transfer of recipient-strain nT-regs had little discernible impact upon transplant outcome, 
transfer of donor strain nT-regs was associated with abrogation of recipient autoantibody 
responses, a reduction in the severity of CAV, and prolonged allograft survival (Figures 4A, B 
and C).  
 
Discussion 
Our results demonstrate that following solid organ transplantation, donor-derived CD4 T 
cells are released into the recipient circulation, and, at least following lung transplantation, 
may persist for some time. Within a larger population of conventional CD4 T effector cells, 
smaller numbers of regulatory T cells can be identified, and our murine studies confirm that 
these can inhibit host adaptive immune responses. These findings may hold particular 
pertinence to ex vivo organ perfusion strategies currently being developed; they highlight 
that rather than blanket depletion, preservation of select passenger lymphocyte subsets 
within the allograft may be beneficial.  
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It is perhaps surprising that donor-derived nT-regs were more effective than recipient-
derived nT-regs at blocking host humoral responses. Although the precise target epitopes 
remain ill-defined (11, 12), nT-regs are thought to recognise specific, self-restricted peptide 
epitopes (typically autoantigens (13)). Donor-derived nT-regs therefore presumably 
recognise intact host MHC class II complexes on recipient cells via the direct-pathway (14), 
and in which case, do so with a much greater precursor frequency than for a self-restricted 
response, with approximately 5% of the clonal repertoire responding (15). We have recently 
demonstrated that this enables naïve donor T cells to provide promiscuous, ’peptide-
degenerate’ help to all host B cells, with plasma cell differentiation dictated by simultaneous 
BCR ligation (6, 16). By extension, recognition of MHC class II alloantigen on host B cells by 
passenger T-regs within the allograft is likely to provide broad inhibition of host humoral 
immunity. Whether this inhibition is the result of direct killing of the B cell by the T-reg (17-
20), or delivery of inhibitory signals to the B cell (21, 22), or blockade of delivery of essential 
help from CD4 T effector cells is as yet unknown and is the subject of ongoing investigation 
in our laboratory.  
 
In addition to providing support for strategies that selectively retain donor T-regs within the 
allograft, our results suggest that donor-derived T-regs may hold potential as a cellular 
therapy for prolonging allograft survival. This would differ from strategies that are currently 
under evaluation clinically, and that typically employ recipient-derived CD4 T-regs that are 
either polyclonal or exhibit direct allospecificity for the donor (23). In similar fashion to 
donor effector CD4 T cells (that provide promiscuous help to all B cells engaging target 
antigen), transferred donor derived T-regs would be expected to inhibit host B cell 
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responses against concurrently encountered alloantigen; even those alloantigens that are 
expressed on the T-reg surface (6). Thus, it seems probable that donor-derived T-regs will be 
effective in transplant models incorporating donor - recipient strain combinations that are 
more MHC-mismatched; certainly, direct-pathway allorecognition of host MHC class II by 
donor-derived T-regs is likely to be at least as robust in more mismatched strain 
combinations as in the bm12 to B6 model. For the same reasoning, we would anticipate that 
bm12 nT-regs could be used as a cellular therapy to block host B cell alloresponses against a 
variety of different donor-strain transplants into B6 recipients. Potency of this approach 
could be enhanced by either increasing the proportion of T-regs within the transferred 
population that exhibit direct-pathway allospecificity, or by first generating memory T-regs 
directed against intact host MHC class II (24). In this regard, it is notable that heart allografts 
that contain memory CD4 T cells specific for host MHC class II (by priming the donor with 
recipient alloantigen six weeks prior to heart donation) are rejected much more rapidly than 
hearts from unmodified donors, with greatly augmented autoantibody responses ((6), 
Qureshi (submitted)). 
 
Such a use of 3
rd
 party T-regs to block host humoral alloimmunity would be distinctly 
different to proposed strategies that differentiate / expand T-regs with self-restricted 
specificity for alloantigen from the individual’s endogenous T cell population (20, 25), and 
may offer a particular advantage. T cell help for alloantibody production can only be 
provided by host CD4 T cells with indirect-allospecificity (26-28). Thus, for maximum 
effectiveness, recipient-derived T-regs would need to recognise the relevant allopeptide 
epitope presented by host MHC class II. Prediction of these peptides is, however, 
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challenging, not least because the repertoire of presented allopeptide peptides may change 
with time (29). In contrast, 3
rd
 party T-regs with direct allospecificity would be expected to 
interact with the individual’s B cells in a peptide-degenerate fashion, and would therefore 
potentially block all concurrently active B cell responses. The crucial attribute in enabling 
donor-derived T-regs to inhibit host  B cell responses is avoidance of recognition and killing 
by host NK cells (6). Thus, only 3
rd
 party donors that are minimally MHC mismatched against 
the individual are likely to be effective. This limitation could possibly be overcome by 
transduction of an individual’s purified nT-reg population with TCR genes (30) that encode 
direct-pathway reactivity to that individual’s own MHC class II, with the relevant Tcrα and 
Tcrβ sequences first established by identifying dividing clones in standard mixed leucocyte 
reactions using 3
rd
 party cells as responders against recipient stimulators (31). This would 
generate autologous CD4 T-regs with heightened specificity for self.  
 
This approach may have wider uses beyond transplantation. It could, for example, be 
refined as a potential treatment for humoral autoimmunity, wherein nT-regs from a 3
rd
 
party donor that have direct-pathway allospecificity for the individual’s (recipient) MHC 
class II antigens would be expected to block cognate interactions between autoreactive B 
and T helper cells in the host; thereby inhibiting autoantibody production.  
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Figures and Legends 
 
Figure 1: Solid organ human transplants contain passenger CD4 T lymphocyte subsets 
(A) Donor HLA class I mismatched antigens were used as a target for detection of donor CD4 
T cell chimerism in lung transplant recipients using flow cytometry. Three patterns of donor 
CD4 T cell chimerism were observed: short-term chimerism (donor CD4 T cells detectable 
for up to six weeks after transplantation [patients 20, 8, 1, 2, 5, 6, 11, 13, 16, 17, 3, 4 and 
19]); intermediate-term chimerism (donor CD4 T cells detectable between 3 and 6 months 
after transplantation [patients 9, 21 and 7]), and long-term chimerism (donor CD4 T cells 
detectable for longer than six months after transplantation [patients 12, 15, 18, 14 and 10]). 
Green dot - blood sample tested and donor CD4 T cells detected. Red dot – blood sample 
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tested, donor CD4 T cells not detected. Black dot – patient died. (B) Representative flow 
cytometry plots for analysis of live CD4 T cells recovered from leukocyte filters of human 
kidney organs undergoing ex vivo normothermic perfusion. Histogram depicts the 
proportion of CD3CD4 T lymphocytes that expressed CD25
hi
CD127
lo
 T regulatory cell surface 
phenotype (n=3).  
 
Figure 2: T-reg depletion augments donor T cell-dependent effector autoantibody 
responses and accelerates allograft rejection. 
MHC-class II mismatched cardiac allografts from wild-type or T cell deficient (TCR
-/-
) bm12 
donor mice were transplanted into unmodified wild-type (WT) C57BL/6 (B6) or T-reg 
depleted recipients and effector autoantibody responses (A), allograft survival (B), and 
allograft vasculopathy at explant on day 100 (C) assessed (allograft vasculopathy for T-reg 
depleted recipients of WT bm12 heart allografts not analysed because of rapid graft 
destruction). T-reg depletion results in augmented autoantibody responses (p =0.04, 
Kruskal-Wallis test) and rapid allograft rejection (* p<0.0001, log-rank test), but this impact 
is dependent upon transfer of passenger donor T cells. Representative EVG staining showing 
allograft vasculopathy in WT recipients compared to non-diseased vessels in (TCR
-/-
) bm12 
hearts transplanted into T-reg depleted recipients (scale bars 100µM). 
*
p =0.03, Mann-
Whitney test. Data is expressed as mean ± SD and represents a minimum of 4 animals per 
group. 
 
Figure 3: Donor T-reg depletion results in exacerbated autoantibody production and 
accelerated graft loss 
Heart allografts from unmodified (wild-type) or T-reg depleted bm12 donor mice were 
transplanted into wild-type C57BL/6 mice and effector autoantibody responses (A) and 
allograft rejection (B) assessed. Compared to unmodified donor hearts, donor T-reg 
depletion results in acute allograft rejection (median survival time (MST) 14 days vs 78 days; 
* p<0.01, log-rank test), with markedly augmented recipient autoantibody responses (** 
p<0.001, 2-way ANOVA). Data expressed as mean ± SD, n=4. 
 
Figure 4: Adoptive transfer of donor nT-reg inhibits recipient autoantibody responses and 
prolongs allograft survival.  
C57BL/6 (B6) recipients of bm12 heart allografts were adoptively transferred the day after 
transplantation with natural T-regs (nT-regs) purified from donor (bm12) or recipient (B6) 
strain and recipient autoantibody responses (A), allograft survival (B) and allograft 
vasculopathy (C) assessed as detailed in Figure 2 legend. Control recipients received no 
treatment. Whereas administration of recipient-strain nT-regs had little impact upon 
rejection responses or rejection kinetics, administration of donor-strain nT-regs inhibited 
effector autoantibody responses (
*
p=0.27, 
**
p<0.001, 2-way ANOVA), prolonged allograft 
survival (MST 91 vs 67 days; * p=0.03. log rank test), and was associated with reduction in 
the severity of allograft vasculopathy (‡ p=0.02, ‡‡ p=0.38; Mann-Whitney test). 
Data are representative of 6 animas per group, and expressed as mean ± SD, n=6.   
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